JPH05508220A - 抗ＩｇＥ自己抗体の検出および調製法およびこれら抗体の診断および治療組成物中での活性剤としての使用 - Google Patents
抗ＩｇＥ自己抗体の検出および調製法およびこれら抗体の診断および治療組成物中での活性剤としての使用Info
- Publication number
- JPH05508220A JPH05508220A JP91508475A JP50847591A JPH05508220A JP H05508220 A JPH05508220 A JP H05508220A JP 91508475 A JP91508475 A JP 91508475A JP 50847591 A JP50847591 A JP 50847591A JP H05508220 A JPH05508220 A JP H05508220A
- Authority
- JP
- Japan
- Prior art keywords
- ige
- antibodies
- autoantibodies
- recombinant
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 45
- 238000001514 detection method Methods 0.000 title claims description 13
- 230000001225 therapeutic effect Effects 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 10
- 239000013543 active substance Substances 0.000 title 1
- 239000013566 allergen Substances 0.000 claims description 37
- 208000026935 allergic disease Diseases 0.000 claims description 22
- 206010020751 Hypersensitivity Diseases 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 19
- 230000007815 allergy Effects 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 13
- 102000018358 immunoglobulin Human genes 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 238000001042 affinity chromatography Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 230000003266 anti-allergic effect Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 238000000151 deposition Methods 0.000 claims description 4
- 238000005194 fractionation Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000020 Nitrocellulose Substances 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000002985 plastic film Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 26
- 238000003556 assay Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 16
- 229960001340 histamine Drugs 0.000 description 13
- 210000003651 basophil Anatomy 0.000 description 8
- 206010002198 Anaphylactic reaction Diseases 0.000 description 7
- 230000036783 anaphylactic response Effects 0.000 description 7
- 208000003455 anaphylaxis Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 229960004784 allergens Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000430 skin reaction Toxicity 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000000138 effect on histamine Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940046528 grass pollen Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000899717 Itaya Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241001424341 Tara spinosa Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- -1 sulfide leukotrienes Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002086605A CA2086605A1 (fr) | 1991-05-10 | 1991-05-10 | Methodes de detection et de preparation des auto-anticorps anti-ige et utilisation de ces anticorps comme agents actifs dans des compositions diagnostiques et therapeutiques |
| PCT/EP1991/000881 WO1992021031A1 (fr) | 1991-05-10 | 1991-05-10 | PROCEDE DE DETECTION ET DE PREPARATION D'AUTOANTICORPS ANTI-IgE, ET UTILISATION DE CES ANTICORPS COMME AGENTS ACTIFS DANS DES COMPOSITIONS A USAGE THERAPEUTIQUE ET DIAGNOSTIQUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05508220A true JPH05508220A (ja) | 1993-11-18 |
Family
ID=4150928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP91508475A Pending JPH05508220A (ja) | 1991-05-10 | 1991-05-10 | 抗ＩｇＥ自己抗体の検出および調製法およびこれら抗体の診断および治療組成物中での活性剤としての使用 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0538266A1 (fr) |
| JP (1) | JPH05508220A (fr) |
| CA (1) | CA2086605A1 (fr) |
| WO (1) | WO1992021031A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011163992A (ja) * | 2010-02-12 | 2011-08-25 | Nitto Boseki Co Ltd | Ｆｔｃｄとその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19505266C1 (de) * | 1995-02-16 | 1996-10-02 | Brahms Diagnostica Gmbh | Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren |
| EP1671646A3 (fr) * | 1998-09-18 | 2007-08-29 | Dynavax Technologies Corporation | Procédés de traitement de troubles associés à IgE et compositions pouvant être utilisées à cet effet. |
| JP2003524602A (ja) * | 1998-09-18 | 2003-08-19 | ダイナバックス テクノロジーズ コーポレイション | ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物 |
| US6787524B2 (en) | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
| RU2006134031A (ru) * | 2004-02-26 | 2008-04-10 | Альк-Абелло А/С (Dk) | Способ оценки терапевтического потенциала вакцины для введения через слизистые оболочки |
| AU2006251647A1 (en) | 2005-05-20 | 2006-11-30 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
| GT200800034A (es) * | 2007-04-02 | 2010-03-16 | Anticuerpos anti-ige | |
| CN113583134B (zh) * | 2020-04-30 | 2024-06-04 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
-
1991
- 1991-05-10 JP JP91508475A patent/JPH05508220A/ja active Pending
- 1991-05-10 WO PCT/EP1991/000881 patent/WO1992021031A1/fr not_active Application Discontinuation
- 1991-05-10 CA CA002086605A patent/CA2086605A1/fr not_active Abandoned
- 1991-05-10 EP EP91909250A patent/EP0538266A1/fr not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011163992A (ja) * | 2010-02-12 | 2011-08-25 | Nitto Boseki Co Ltd | Ｆｔｃｄとその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2086605A1 (fr) | 1992-11-11 |
| EP0538266A1 (fr) | 1993-04-28 |
| WO1992021031A1 (fr) | 1992-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maurer et al. | The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. | |
| Brindley et al. | The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. | |
| Gleich et al. | Immunoglobulin E antibodies to pollen allergens account for high percentages of total immunoglobulin E protein | |
| Paull et al. | Melittin: an allergen of honeybee venom | |
| US5766590A (en) | Therapeutic methods and pharmaceutical compositions | |
| JP2011099871A (ja) | 新規組成物 | |
| AU693992B2 (en) | Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples | |
| DE202006020682U1 (de) | Mittel zur Diagnose von rheumatischen Erkrankungen | |
| Gieras et al. | Molecular determinants of allergen-induced effector cell degranulation | |
| DeBoer et al. | Production and characterization of mouse monoclonal antibodies directed against canine IgE and IgG | |
| Terness et al. | The natural human IgG anti-F (ab') 2 antibody recognizes a conformational IgG1 hinge epitope. | |
| WO1996020958A9 (fr) | Anticorps monoclonaux specifiques pour une glycosylation avancee de produits terminaux dans des echantillons biologiques | |
| JPH05508220A (ja) | 抗ＩｇＥ自己抗体の検出および調製法およびこれら抗体の診断および治療組成物中での活性剤としての使用 | |
| JP3778936B2 (ja) | インシュリン依存性糖尿病（ｉｄｄｍ）患者に作用する免疫反応および免疫治療分子 | |
| WO1999064463A1 (fr) | Anticorps monoclonaux specifiques de produits finaux de glycosylation avancee derives de groupes guanidino dans des echantillons biologiques | |
| Wells et al. | Antibodies to human collagen in subjects with selective IgA deficiency | |
| Kobayashi et al. | Detection of Fcγ binding protein antigen in human sera and its relation with autoimmune diseases | |
| Bystryn | Clinical significance of basal cell layer antibodies | |
| JPH10509948A (ja) | Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法 | |
| US20030007973A1 (en) | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody | |
| KR101156523B1 (ko) | 아토피성 피부염 유도 물질 | |
| Evans et al. | In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin | |
| Hemmens et al. | Common antigenic and allergenic determinants on codfish proteins detected with mouse monoclonal IgG and human IgE antibodies | |
| Griot-Wenk et al. | Characterization of two dog IgE-specific antibodies elicited by different recombinant fragments of the epsilon chain in hens | |
| Homburger et al. | Diagnosis of allergy: in vitro testing |